Cancer Therapeutics Program

癌症治疗学文摘：摘要 癌症治疗（CT）计划的首要目标是通过以下方式转化发现：1） 开发新的治疗药物，2）生物技术和生物工程方法，以及3）创新 临床试验，以加强癌症诊断和治疗，并改善患者的结果。CT是一种新的 该CCSG应用程序中的程序，由于临床和转化研究的显着增长 在实体和血液肿瘤和SCC的前三个项目的战略调整。得更好 将SCC定位为这些地区的战略驱动型增长，并允许更大的集水区影响。 CT计划是由莱西麦克纳利，博士和凯瑟琳摩尔，医学博士，谁带来了互补 在开发药物和技术方面的专业知识，并将其转化为临床试验， 对癌症患者有积极的影响。 2021年，CT计划有38名成员（23名正式成员，15名副成员），代表13个学术部门， 两个校区（31个在OUHSC; 7个在诺曼）。在这38名成员中，有20名是医学博士，这强调了需要 在SCC内为临床试验者和临床科学家提供一个专注于所有癌症的计划性家园 类型另外75个CT附属成员（非CCSG类别），包括许多SCC临床医生 研究人员，帮助推进CT计划的目标。同行评审的研究资金总额为654万美元，其中 433万美元来自NCI（年度直接成本）。值得注意的是，NCI资金占同行评审总数的66% 资金，突出CT计划的强烈癌症重点。经同行评审的研究资金总额 在赠款周期内增加了29%（506万美元至654万美元），NCI增加了34%（323万美元至433万美元）。 同行评审项目的数量从23个（2017年）增加到35个（2021年），增加了52%，突出了 方案的增长和研究活动的多样性。CT成员在同行中发表了755篇手稿， 在过去五年中的期刊评论（3.97 /成员/年）。其中，154人（20%）是在 其中，190个（25%）是跨方案的，570个（75%）是多机构的，表明 CT成员之间的高度合作，与其他SCC计划的成员，以及与 其他机构的调查员。重要的是，161篇（21%）CT成员出版物发表在高... 影响力期刊（影响因子≥10）。在本报告所述期间，有3，652名患者参加了CT临床试验。 试验，包括3，095项介入治疗试验。每年活跃的CT成员干预人数 治疗IIT从4个（2017年）增加到21个（2021年），突出了扩大的深度和广度， 翻译活动源于程序。

CANCER THERAPEUTICS PROGRAM: ABSTRACT The overarching goal of the Cancer Therapeutics (CT) program is to translate discoveries through: 1) development of new therapeutic agents, 2) biotechnology and bioengineering approaches, and 3) innovative clinical trials in order to enhance cancer diagnosis and treatment and improve patient outcomes. CT is a new program in this CCSG application, resulting from the significant growth of clinical and translational research across solid and hematologic tumors and a strategic realignment of the SCC’s former three programs. It better positions the SCC for strategically driven growth in these areas and allows for greater catchment area impact. The CT program is led by Lacey McNally, PhD and Kathleen Moore, MD, who bring complementary expertise in developing agents and technologies and translating these into clinical trials that can have a positive impact on patients with cancer. In 2021, the CT program had 38 members (23 full, 15 associate), representing 13 academic departments at two campuses (31 at OUHSC; 7 at OU Norman). Of these 38 members, 20 are MDs, underscoring the need to have a programmatic home within the SCC for clinical trialists and clinician scientists focused in all cancer types. An additional 75 CT affiliate members (non-CCSG category), including many SCC clinician investigators, help advance CT program aims. Total peer-reviewed research funding was $6.54M, of which $4.33M was from NCI (annual, direct cost). Significantly, NCI funding accounts for 66% of total peer-reviewed funding, highlighting the strong cancer-focus of the CT program. Total peer-reviewed research funding increased by 29% over the grant cycle ($5.06M to $6.54M), with NCI increasing by 34% ($3.23M to $4.33M). The number of peer-reviewed projects rose from 23 (2017) to 35 (2021), a 52% increase highlighting programmatic growth and diversity of research activity. CT members published 755 manuscripts in peer- reviewed journals over the past five years (3.97 / member / year). Of these, 154 (20%) were intra- programmatic, 190 (25%) were inter-programmatic, and 570 (75%) were multi-institutional, demonstrating the high degree of collaboration between CT members, with members in other SCC programs, and with investigators at other institutions. Importantly, 161 (21%) of CT member publications were published in high- impact journals (impact factor ≥10). During the reporting period, 3,652 patients were accrued to CT clinical trials, including 3,095 to interventional treatment trials. The number of annual active CT member interventional treatment IITs increased from 4 (2017) to 21 (2021), highlighting the expanding depth and breadth of translational activity emanating from the program.